Tokyo Tape
Sign in
← I'rom Group

Quarterly report · Q3

2372.TEDINET S100Q33O
Period2022-04-01 → 2022-12-31
Filed2023-02-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥13.9bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥15.7bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥11.7bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥3.0bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥2.2bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥2.9bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥2.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.3bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥3.0bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥2.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥2.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.8bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥2.2bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥1.8bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥32.2bnat 2022-12-31Cons.Assets
Total assets¥26.6bnat 2022-03-31Cons.Assets
Total assets¥26.1bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥20.4bnat 2022-12-31Cons.Liabilities
Total liabilities¥16.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥11.8bnat 2022-12-31Cons.Net assets
Net assets / equity¥10.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥9.9bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥8.3bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥6.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥185.132022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.052022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥162.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥147.382021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.362021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥184.942022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥162.172021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥147.062021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio36.7%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio38.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio37.7%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥104m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥58m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥46m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥237m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥953m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥953m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥996m
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentrevenue2022-04-01 → 2022-12-31¥1.1bn
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.1bn
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2m
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentsegment profit2022-04-01 → 2022-12-31−¥100m
jpcrp040300-q3r_E05352-000CROreportable segmentrevenue2022-04-01 → 2022-12-31¥4.1bn
jpcrp040300-q3r_E05352-000CROreportable segmentrevenue external2022-04-01 → 2022-12-31¥4.0bn
jpcrp040300-q3r_E05352-000CROreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥97m
jpcrp040300-q3r_E05352-000CROreportable segmentsegment profit2022-04-01 → 2022-12-31−¥70m
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentrevenue2022-04-01 → 2022-12-31¥1.5bn
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentrevenue external2022-04-01 → 2022-12-31¥776m
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentsegment profit2022-04-01 → 2022-12-31¥69m
jpcrp040300-q3r_E05352-000SMOreportable segmentrevenue2022-04-01 → 2022-12-31¥8.1bn
jpcrp040300-q3r_E05352-000SMOreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E05352-000SMOreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥115m
jpcrp040300-q3r_E05352-000SMOreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.4bn
—segment totalrevenue2022-04-01 → 2022-12-31¥14.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥13.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥907m
—segment totalsegment profit2022-04-01 → 2022-12-31¥4.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥14.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥13.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥953m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥4.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥55m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥12m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥43m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31−¥142m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥811m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥811m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.0bn
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentrevenue2021-04-01 → 2021-12-31¥489m
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentrevenue external2021-04-01 → 2021-12-31¥486m
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥3m
jpcrp040300-q3r_E05352-000Advanced Medicalreportable segmentsegment profit2021-04-01 → 2021-12-31−¥452m
jpcrp040300-q3r_E05352-000CROreportable segmentrevenue2021-04-01 → 2021-12-31¥3.8bn
jpcrp040300-q3r_E05352-000CROreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.7bn
jpcrp040300-q3r_E05352-000CROreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥50m
jpcrp040300-q3r_E05352-000CROreportable segmentsegment profit2021-04-01 → 2021-12-31¥435m
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentrevenue2021-04-01 → 2021-12-31¥1.4bn
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentrevenue external2021-04-01 → 2021-12-31¥774m
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥589m
jpcrp040300-q3r_E05352-000Medical Supportreportable segmentsegment profit2021-04-01 → 2021-12-31¥233m
jpcrp040300-q3r_E05352-000SMOreportable segmentrevenue2021-04-01 → 2021-12-31¥6.8bn
jpcrp040300-q3r_E05352-000SMOreportable segmentrevenue external2021-04-01 → 2021-12-31¥6.7bn
jpcrp040300-q3r_E05352-000SMOreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥124m
jpcrp040300-q3r_E05352-000SMOreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.1bn
—segment totalrevenue2021-04-01 → 2021-12-31¥12.4bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥11.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥767m
—segment totalsegment profit2021-04-01 → 2021-12-31¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥12.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥11.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥811m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥3.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 416
ItemContextValueUnit
Capital surplusPrior1YearInstant1466000000JPY
Capital surplusCurrentQuarterInstant1495000000JPY
Retained earningsPrior1YearInstant5099000000JPY
Retained earningsCurrentQuarterInstant6732000000JPY
Treasury stockPrior1YearInstant-423000000JPY
Treasury stockCurrentQuarterInstant-424000000JPY
Shareholders equityPrior1YearInstant10021000000JPY
Shareholders equityCurrentQuarterInstant11702000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant68000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant90000000JPY
Foreign currency translation adjustmentPrior1YearInstant38000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant37000000JPY
Valuation and translation adjustmentsPrior1YearInstant107000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant128000000JPY
Subscription rights to sharesPrior1YearInstant17000000JPY
Subscription rights to sharesCurrentQuarterInstant－JPY
Non controlling interestsPrior1YearInstant16000000JPY
Non controlling interestsCurrentQuarterInstant6000000JPY
Net assetsPrior1YearInstant10162000000JPY
Net assetsCurrentQuarterInstant11836000000JPY
Liabilities and net assetsPrior1YearInstant26588000000JPY
Liabilities and net assetsCurrentQuarterInstant32221000000JPY
Net salesPrior1YTDDuration11676000000JPY
Net salesCurrentYTDDuration13896000000JPY
Cost of salesPrior1YTDDuration6144000000JPY
Cost of salesCurrentYTDDuration7015000000JPY
Gross profitPrior1YTDDuration5531000000JPY
Gross profitCurrentYTDDuration6881000000JPY
Directors compensations sgaPrior1YTDDuration361000000JPY
Directors compensations sgaCurrentYTDDuration364000000JPY
Salaries allowances and bonuses sgaPrior1YTDDuration1199000000JPY
Salaries allowances and bonuses sgaCurrentYTDDuration1520000000JPY
Commission fee sgaPrior1YTDDuration134000000JPY
Commission fee sgaCurrentYTDDuration137000000JPY
Rent expenses sgaPrior1YTDDuration268000000JPY
Rent expenses sgaCurrentYTDDuration315000000JPY
Research and development expenses sgaPrior1YTDDuration491000000JPY
Research and development expenses sgaCurrentYTDDuration495000000JPY
Other sgaPrior1YTDDuration879000000JPY
Other sgaCurrentYTDDuration1018000000JPY
Selling general and administrative expensesPrior1YTDDuration3334000000JPY
Selling general and administrative expensesCurrentYTDDuration3853000000JPY
Operating incomePrior1YTDDuration2197000000JPY
Operating incomeCurrentYTDDuration3027000000JPY
Interest income noiPrior1YTDDuration21000000JPY
Interest income noiCurrentYTDDuration97000000JPY
Dividends income noiPrior1YTDDuration7000000JPY
Dividends income noiCurrentYTDDuration0JPY
Gain on sales of investment securities noiPrior1YTDDuration183000000JPY
Gain on sales of investment securities noiCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass